Cost-Effectiveness of an Obesity Management Program for 6- to 15-Year-Old Children in Poland: Data from Over Three

Ewa Bandurska1, Michał Brzeziński2,3, Paulina Metelska1,4

  • 1Department of Public Health and Social Medicine, Medical University of Gdansk, Gdansk, Poland.

Obesity Facts
|September 21, 2020
PubMed

Insights

The 6-10-14 for Health program is a cost-effective intervention for childhood obesity. It successfully improved weight indicators in about half of participating children, demonstrating value in public health initiatives.

Area of Science:

  • Public Health
  • Pediatrics
  • Health Economics

Background:

  • Childhood obesity is a significant global public health issue requiring effective interventions.
  • Long-term strategies involving diet, physical activity, and psychological support are key for pediatric weight management.
  • Limited research exists on the financial effectiveness of childhood obesity interventions.

Purpose of the Study:

  • To assess the cost-effectiveness of the 6-10-14 for Health weight management program.
  • Utilize pharmacoeconomic indicators, specifically the incremental cost-effectiveness ratio, for evaluation.

Main Methods:

  • Involved anthropometric data from 3,081 children over a 1-year intervention.
  • Conducted a comprehensive financial cost assessment of the program.

Main Results:

  • The cost to reduce a child from overweight (BMI >85th percentile) was EUR 6,463.
  • The cost to reduce a child from obese (BMI >95th percentile) was EUR 5,495.
  • Program costs were comparable to multi-component school-based interventions.

Conclusions:

  • The 6-10-14 for Health program demonstrates cost-effectiveness.
  • An investment of approximately EUR 1,790 per child led to improved weight indicators in about 50% of participants.
  • The intervention offers encouraging results when considering long-term obesity-related medical costs.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.0K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
119
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
134
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
96